BioCentury

@BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: bit.ly/4b1HDDu

Redwood City, Calif.

biocentury.com

Replies Reposts Media

BioCentury
@BioCentury
18h
Radiopharma financing continues to grow as U.S. and China drive equity growth, while Telix debt lifts Australia
Led by the U.S. and China, radiopharma financing reaches new heights
From biocentury.com
1
BioCentury
@BioCentury
18h
Guidance leaves critical questions unanswered a week before tariffs take effect
Tariff guidance leaves companies in the dark
From biocentury.com
1
BioCentury
@BioCentury
19h
ShennonBio: Mining rare T cells for target solid tumor therapies. DCVC-backed Harvard spinout builds three-candidate T cell engager pipeline with functional screening platform. An Emerging Company Profile by BioCentury's Lindsay Martin
ShennonBio: Mining rare T cells for solid tumor therapies
From biocentury.com
1
BioCentury
@BioCentury
Sep 22
In BioCentury's Deals Report: Telix takes latest step toward broad global ambitions with ITM takeout; plus GSK-Chimagen; Novartis-Sironax; Roche-Dualitas; and more
Telix-ITM merger aims to create radiopharma juggernaut: Deals Report
From biocentury.com
BioCentury
@BioCentury
Sep 22
Biotech IPOs, autoimmune CAR T safety and pharma tariffs — the latest #BioCenturyThisWeek podcast is available now on BioCentury.com, Apple, Spotify & YouTube buff.ly/MLhjlxl
1